ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.96
-1.13%
US Tech 100
18,062.80
-0.34%
S&P 500
5,260.58
-0.43%
US Dollar vs CAD
1.36872
0.42%
Bitcoin
70,699.99
2.76%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) News

SAN

Sanofi (SAN)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:EU:SAN
DateTimeSourceHeadlineSymbolCompany
06/03/20243:15PMGlobeNewswire Inc.Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]EU:SANSanofi
06/03/20243:15PMGlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
06/03/20243:15PMGlobeNewswire Inc.Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3EU:SANSanofi
05/31/20245:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salariéEU:SANSanofi
05/31/20245:00AMGlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
05/31/20245:00AMGlobeNewswire Inc.Press Release: Sanofi launches 2024 global Employee Stock Purchase PlanEU:SANSanofi
05/31/202412:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
05/31/202412:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
05/31/202412:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
05/31/202412:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
05/31/202412:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
05/31/202412:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
05/31/202412:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
05/30/20248:01AMGlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
05/30/20248:01AMGlobeNewswire Inc.Press Release: Sanofi completes acquisition of Inhibrx, Inc.EU:SANSanofi
05/30/20248:01AMGlobeNewswire Inc.Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.EU:SANSanofi
05/27/202412:00AMGlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
05/27/202412:00AMGlobeNewswire Inc.Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaEU:SANSanofi
05/27/202412:00AMGlobeNewswire Inc.Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantationEU:SANSanofi
05/21/202412:30AMGlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
05/21/202412:30AMGlobeNewswire Inc.Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IAEU:SANSanofi
05/21/202412:30AMGlobeNewswire Inc.Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaborationEU:SANSanofi
05/20/20243:54PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - April 2024EU:SANSanofi
05/20/20243:54PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024EU:SANSanofi
05/20/20241:15PMGlobeNewswire Inc.Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCOEU:SANSanofi
05/20/20241:15PMGlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
05/20/20241:15PMGlobeNewswire Inc.Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMEU:SANSanofi
05/13/202412:00AMGlobeNewswire Inc.Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaireEU:SANSanofi
05/13/202412:00AMGlobeNewswire Inc.Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereigntyEU:SANSanofi
05/13/202412:00AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)EU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Your Recent History

CRTO
CSPRUSD
Casper
BITMOT
942877
Centro Lars Tf 5% Mg29 A...
EU
BMIE
Bass Master Issuer BMI C...
ASX
OBM
Ora Banda Mining
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved